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Aspergillosis has been the prevailing deep-seated mycosis in Japan since the 1990s. Although 
micafungin (MCFG) has been approved in Japan for the management of patients with 
deep-seated mycosis caused by Candida species or Aspergillus species, there are relatively few 
reports on its use in patients with chronic pulmonary aspergillosis (CPA). 
Objectives 
A prospective observational study was conducted to evaluate the efficacy and safety of 
MCFG in Japanese patients with CPA. 
Methods 
The efficacy of MCFG in CPA patients was assessed based on improvements in clinical 
symptoms and radiological findings. In addition, adverse events, including abnormal 
laboratory findings were assessed. 
Results 
The overall clinical efficacy rate was 68.4% (26/38 patients), which is comparable to the 
results of the clinical trial for marketing approval conducted in Japan. Adverse drug reactions 
were observed in 6 patients (15.8%); none of which were serious. The most common adverse 
drug reaction being abnormal liver functions. No relation between the incidence of adverse 
drug reactions and age, MCFG dose, or duration of treatment was observed. 
 4
Conclusions 




 The incidence of deep-seated mycosis, especially aspergillosis, has increased in 
recent years [1, 2]. Based on pathology autopsy cases including Japanese patients, 
aspergillosis has been considered the prevailing deep-seated mycosis since the 1990s [3, 4]. 
An increasing number of immunocompromised patients associated with acquired 
immunodeficiency syndrome, bone marrow transplantation, or chemotherapy is considered to 
be the main contributing population to this growing prevalence of aspergillosis [5, 6]. 
 Pulmonary aspergillosis is classified into three major categories, invasive pulmonary 
aspergillosis (IPA), chronic pulmonary aspergillosis (CPA) including chronic necrotizimg 
pulmonary aspergillosis (CNPA), chronic cavitary pulmonary aspergillosis (CCPA also known 
as complex aspergilloma), chronic fibrosing pulmonary aspergillosis (CFPA) and simple 
aspergilloma [7, 8]. IPA often occurs in patients after hematopoietic stem cell transplantation 
or with severe hematological disorders such as acute leukemia [5, 6, 9-11]. IPA rapidly 
progresses, and a definite diagnosis is generally deemed difficult [5, 12]. CPA can occur in 
patients with underlying respiratory diseases such as tuberculosis sequelae, chronic 
obstructive pulmonary disease, or associated with pulmonary surgery, radiotherapy, 
pneumococcal infection, diabetes mellitus, collagen disease, corticosteroid-induced 
immunosuppressive conditions. In most cases, CPA requires long-term treatment [7, 8, 13], 
however, limited evidence is available for CPA management. 
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 Micafungin (MCFG), an echinocandin antifungal agent, is a selective inhibitor of the 
synthesis of (1,3)-beta-D-glucan, a primary component of fungal cell walls. MCFG exerts its 
fungicidal action on Candida, and causes rupture of mycelial tips of Aspergillus by the potent 
inhibition of mycelial extension [14-17]. Although various clinical studies that demonstrate 
the effectiveness of MCFG for invasive fungal infections have been reported [18-29], there 
are few reports on its use for the treatment of CPA [25, 30]. We recently published the first 
large scale prospective study comparing the efficacies of intravenous MCFG and intravenous 
voriconazole in the treatment of CPA [31]. There was a favorable response rate with both 
MCFG (60.0%) and voriconazole (53.2%); however fewer side effects were reported for 
MCFG (26.4%) than for voriconazole (61.1%) [31]. We also had conducted another 
prospective observational study to clarify the efficacy and safety profile of MCFG with 38 
CPA patients from 28 Japanese medical institutions between April 2003 and March 2005. This 
study is relatively small, non-randomized observational study, however, the information 
obtained from a clinical setting could be also beneficial for clinicians facing CPA. 
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Materials and Methods 
Study Patients 
 The enrollment criteria for prospective clinical studies of CPA proposed by 
Denning et al. [7] was slightly modified, and utilized in this study. Briefly, patients were 
enrolled in this study if they had clinical symptoms caused by pulmonary Aspergillosis [any 
of cough, sputum, hemosputum, haemoptysis, and pyrexia (≥ 37.0°C axillary temperature)], 
and elevated levels of inflammatory markers (any of C-reactive protein value, white blood 
cell count, and erythrocyte sedimentation) before the treatment with MCFG, and if they met  
at least one of the following three criteria: 
1) A causative fungus (Aspergillus spp.) identified by cultural or histopathological 
examination. 
2) The appearance of new nodules or the expansion of the existing nodules on a chest X-ray 
or computed tomography (CT) suspected by aspergillosis and with positive result of the 
serological or mycological tests. 
3) Suspected complex aspergilloma with positive feature on a chest X-ray or CT. 
 Patients with features of invasive pulmonary aspergillosis (i.e. symptoms of less than 
1 month) and allergic bronchopulmonary aspergillosis were excluded. 
Patients were treated with MCFG for 4-84 days with doses of 50-150 mg once daily 
by intravenous drip infusion. In severe or refractory cases, a dose increase up to 300 mg daily 
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was allowed. The dose of MCFG was accepted to be changed by the decision of attending 
physicians depending on the severity of disease, since no data was available about the dose 
effect of MCFG. 
 The following information was reviewed from the patient’s medical records, patient 
characteristics (e.g., sex, age, body weight), treatment conditions (e.g., dose of MCFG, 
duration of MCFG therapy, all other antifungals or antibiotics used during the 7 days prior to 
the initiation of MCFG therapy, other concomitant therapies), clinical symptoms or findings, 
radiological findings of chest X-ray, CT, and adverse events. 
 This study was approved by the Institutional Review Board at each institution. Since 
this was an observational study, informed consent was not required. 
 
Efficacy Assessment 
 The efficacy of MCFG was assessed based on improvements in CPA-related clinical 
symptoms and radiological findings such as chest X-ray and CT. Improvement in clinical 
symptoms were rated as “improved,” “worsened” or “unchanged.” Changes in the radiological 
findings of chest X-ray and CT were rated as “improved” when the shadows on the images 
were reduced or diminished, “worsened” when the shadows were increased, and “unchanged” 
otherwise. 
 Overall clinical efficacy (“effective” or “not effective”) was assessed based on the 
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improvement in both ratings of clinical symptoms and radiological findings. Overall clinical 
efficacy was assessed as “effective” when clinical symptoms were rated as “improved” and 
radiological findings were not rated as “worsened.” Overall clinical efficacy was also assessed 
as “effective” when radiological findings were rated as “improved” and the clinical symptom 
was not rated as “worsened.” Overall clinical efficacy was assessed as “not effective” when 
both the clinical symptoms and the radiological findings were rated as “unchanged” or either 
of them was rated as “worsened.” 
 
Safety Assessment 
 All adverse events, including abnormal laboratory findings noted after the initiation 
of MCFG therapy, were recorded. Adverse events that the investigator suspected to have a 
causal relationship with MCFG were classified as adverse drug reactions, and the seriousness 
was classified into three levels of “mild,” “moderate (neither mild nor serious),” and “serious” 
in accordance with the ICH Harmonised Tripartite Guideline [32]. 
 
Statistical Analysis 
The data were expressed as mean ± SD. Categoric variables were expressed as a percentage 





 Table 1 summarizes patient characteristics. The patients consisted of 25 males 
(65.8%) and 13 females (34.2%). Patients aged 65 or older predominated (27 patients [71.1%], 
maximum; 90 years, mean: 68.8 years). The mean body weight was 45.1 kg. 
 The duration of MCFG therapy was 14 days or less in 6 patients (15.8%), 15-28 days 
in 13 patients (34.2%), and 29 days or longer (up to a maximum of 84 days) in the remaining 
19 patients (50.0%). The mean duration was 33.7 ± 19.9 days. The mean daily dose was 167.0 
± 54.4 mg/day, with approximately half of the patients (55.3%) receiving 150 mg/day. 
 
Clinical Efficacy 
1) Clinical response by clinical symptoms and radiological findings (Table 2) 
Overall clinical efficacy was assessed as “effective” in 26 patients (overall clinical efficacy 
rate: 68.4%). Among them, 10 patients showed improvement in both clinical symptoms and 
radiological findings, and the remaining 16 patients showed improvements in either clinical 
symptoms or radiological findings. Of the 12 patients in which overall clinical efficacy was 
assessed as “not effective”, 2 patients showed worsening in both clinical symptoms and 
radiological findings, and 10 patients showed worsening in either clinical symptoms or 
radiological findings. 
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2) Clinical response by duration of treatment and mean daily dose (Table 3) 
The observed clinical efficacy rate when analyzed by duration of treatment was 
lower in patients treated for 14 days or less (3/6 patients) than in the other groups. The 
efficacy rate were 92.3% in patients treated for 15-28 days, and 57.9% in patients treated for 
29-84 days. 
The clinical efficacy rate treated with 100 mg/day, more than 100 mg/day and less 
than 150 mg/day, 150 mg/day, more than 150 mg/day and less than 300 mg/day, 300 mg/day 
were 100.0% (3/3 patients), 80.0% (4/5 patients), 66.7% (14/21 patients), 60.0% (3/5 patients), 
and 50.0% (2/4 patients), respectively. 
 
Safety 
1) Incidence of adverse drug reactions (Table 4) 
 A total of 38 adverse events occurred in 16 of 38 patients. Of them, 10 events in 6 
patients (15.8%) were regarded as adverse drug reactions related to MCFG. 
 Common adverse drug reactions were reported as 7 events of abnormal liver 
functions including increased aspartate aminotransferase (AST), alanine aminotransferase 
(ALT), gamma-glutamyltransferase (γ-GT), and blood alkaline phosphatase (ALP). Among 
the 10 adverse drug reactions, the seriousness was classified as moderate for 5 reactions and 
mild for 5 reactions. No serious adverse drug reactions classified by the ICH guideline [32] 
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were observed. Treatment with MCFG was discontinued in one patient because of increases of 
AST from 40 U/L to 199 U/L and ALT from 36 U/L to 175 U/L. The investigator assessed 
these events as moderate, and suggested the contribution of concomitant drugs such as 
arbekacin and imipenem/cilastatin. 
2) Incidence of adverse drug reactions by age, dose, and duration (Table 5) 
 The incidence of adverse drug reactions by age was 9.1% (1/11 patients) in patients 
aged under 65 years and 18.5% (5/27 patients) in those aged 65 years or older. The latter age 
group of 65 years or older included 6 patients aged 80 years or older, in whom the incidence 
of adverse drug reactions was 16.7% (1/6 patients). 
 The incidence of adverse drug reactions in patients treated with 150 mg/day was 
19.0% (4/21 patients). The remaining 2 patients, in whom adverse drug reactions were 
observed, were treated with 117 mg/day and 300 mg/day, respectively. The incidence of 
adverse drug reactions by duration of treatment was 33.3% (2/6 patients) in patients treated 
for 14 days or less, 15.4% (2/13 patients) in patients treated for 15-28 days, and 10.5% (2/19 




 A multicenter, observational study of 38 CPA patients treated with MCFG showed 
that the overall clinical efficacy rate was 68.4% (26/38 patients), which is comparable to the 
results of our previous studies [25,31], though the design of studies are different. CPA in 
which mycelia do not penetrate the surrounding cavity wall is generally defined as simple 
aspergilloma, but in practice it is often difficult to clearly distinguish between CNPA, CCPA, 
and CFPA. Indeed, Hope et al. consider these pathological conditions to be a continuous series 
of the infection process [13]. In consideration of such circumstance, we considered the 
enrollment criteria proposed by Denning et al. [7] the most practical, and utilized it as 
inclusion criteria in this study.  
The clinical trial of MCFG conducted for marketing approval also demonstrated 
clinical efficacy rates of 67% (6/9 patients) for CNPA, and 55% (12/22 patients) for 
aspergilloma [25]. The efficacy of MCFG shown in this study with patients of various 
backgrounds in a post-marketing setting seems comparable with that of the above-mentioned 
trial, although there are still differences in methodology, baseline patient characteristics, 
dosage regimen, and timing of assessment. 
The Infectious Diseases Society of America guidelines for aspergillosis recommend 
MCFG as an alternative therapy to voriconazole for CNPA and CCPA. For simple 
aspergilloma, the guidelines recommend surgical resection as the primary treatment, and oral 
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itraconazole and voriconazole as alternative therapies in unresectable cases [8]. In our 
previous studies including this study, MCFG achieved an overall clinical efficacy rate of 
approximately 60-70%. This result and result from comparing study with MCFG and 
voriconazole suggests that MCFG has potential as an alternative therapy to itraconazole 
and/or voriconazole. 
 There are no significant differences between the efficacy and the dose of MCFG. 
However, the clinical efficacy rate in the patients who were treated more than 150mg was 
relatively lower than other patients. Nine of the patients who were treated with more than 150 
mg/day included 5 responders and 4 non-responders. No obvious differences were found in 
clinical symptoms/inflammatory findings at the start of MCFG treatment between these 
responders and non-responders. On the other hand, a comparison of the radiological findings 
revealed that only 1 of 5 responders was assessed to have severe disease represented by 
shadows covering 2/3 or more of either lung field, whereas 3 of 4 non-responders were 
considered to have severe disease with shadows covering almost the entire lung field 
unilaterally. In order to clarify the relationship between the severity of the disease and the 
MCFG dose, an additional clinical study in a larger patient population will be needed in the 
future. 
 It is difficult to draw a clear conclusion on the appropriate duration of treatment of 
MCFG from this observational study, in which each investigator determined whether MCFG 
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therapy should be continued or discontinued. However, the patients treated with MCFG for 
15-28 days and those treated for 29 days or longer showed slightly higher efficacy rates in 
comparison with those discontinued within 14 days, and most of patients had been treated for 
more than 14 days. These data may suggest that treatment for more than 14 days is 
recommended for anticipating the sufficient efficacy of MCFG, although the number of 
patients treated for up to 14 days was limited in this study. Therefore, the appropriate duration 
of treatment based on each patient’s condition should further be explored in the future.  
With regard to the safety of MCFG, the incidence of adverse drug reactions was 15.8% 
(6/38 patients), and abnormal liver functions were the most reported adverse drug reactions. In 
the Japanese open-label, non-controlled clinical trial of MCFG in 70 deep-seated mycosis 
patients for marketing approval, 33 adverse drug reactions occurred in 21 patients (incidence: 
30.0%) [25]. Our MCFG and voriconazole comparative study also indicated incidence rate of 
26.4%, which is not different from previous study [31]. Common reactions included increases 
in hepatic enzymes like γ-GT and blood ALP, blood urea nitrogen, and creatinine. None of 
these reactions were assessed as serious [25, 31]. Even though the present study was 
conducted in CPA patients with varying backgrounds, no marked differences were found 
between these three studies concerning the type or seriousness of the adverse drug reactions. 
 When the incidence of adverse drug reactions was analyzed in terms of factors that 
may affect their incidence, no relationship was observed between the incidence of adverse 
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drug reactions and increase in age, dose or duration of treatment. In addition, we were able to 
assess adverse drug reactions in patients not enrolled in the clinical trial of MCFG for 
marketing approval, particularly patients aged 80 years or older, in patients treated at a dose of 
more than 150 mg/day and treated for 57 days and longer. The only adverse drug reaction 
reported in the patient aged 80 years or older was an abnormal liver function, which did not 
result in discontinuation of the treatment and was reported to have subsided 24 days after 
onset. The patient treated at a dose of more than 150 mg/day experienced 3 events of 
abnormal liver functions, of which 2 were classified as moderate and 1 as mild. Concomitant 
drugs such as arbekacin and imipenem/cilastatin may also have contributed to the onset of 
these adverse drug reactions, as well as MCFG, in this patient. The outcomes of these adverse 
drug reactions were not traceable in this case because of death caused by aggravation of the 
underlying disease. No adverse drug reaction was observed after treatment with MCFG for 57 
and longer. 
 In conclusion, MCFG achieved satisfactory treatment results in CPA patients with 
varying backgrounds. The safety profiles of MCFG obtained from this study was similar with 
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Table 1. Patient characteristics 





Age (years)  
23 to 64  11 
65 to 90 27 
(Mean± SD)  (68.8±10.9) 
Body weight (kg)   
(Mean± SD) (45.1±10.6) 
Duration of treatment (days)  
4 to 14  6 
15 to 28  13 
29 to 84  19 
(Mean± SD) (33.7±19.9) 
Mean daily dose (mg/day)   
100   3 
> 100 to < 150  5 
 150 21 
> 150 to < 300  5 
 300 4 
(Mean± SD) (167.0±54.4) 
     Mean± SD; Mean± Standard Deviation 
 23
Table 2. Clinical response by clinical symptoms and radiological findings 
Clinical Response (%) Clinical symptoms  
 




improved (23) * 
 
improved  (10) * 
unchanged (13) * 
unchanged (3) * improved   (3) * 
not effective 
12/38 (31.6%) 
unchanged (6) * 
 
unchanged (4) * 
worsened  (2) * 
worsened  (6) * 
 
unchanged (4) * 
worsened  (2) * 




Table 3. Clinical efficacy rates by duration of treatment with micafungin and mean daily dose
Variable Clinical efficacy rate (%) Statistical test* 
Total 26/38 (68.4) - 
Duration of treatment (days)   
4 to 14  3/6 (50.0) p=0.050 
15 to 28  12/13 (92.3)  
29 to 84  11/19 (57.9)  
Mean daily dose (mg)  
100   3/3 (100.0) p=0.786 
> 100 to < 150 4/5 (80.0)  
150 14/21 (66.7)  
> 150 to < 300   3/5 (60.0)  
300 2/4 (50.0)  





Table 4. Profile of adverse drug reactions (by seriousness) 




Serious Moderate Mild 
Abnormal liver function 7 0 3 4 
(including increased AST, ALT, gamma-GT, and 
ALP) 
          
Injection site extravasation 1 0 1 0 
Edema peripheral 1 0 1 0 
Eosinophil count increased 1 0 0 1 
Total 10 0 5 5 
*Note) : Determined by investigator to be definitely, probably, or possibly drug related. 
AST; aspartate aminotransferase, ALT; alanine aminotransferase, 




Table 5. Incidence of adverse drug reactions by age,  
mean daily dose or duration of treatment 
Variable 
Incidence of  
adverse drug reactions (%) 
Statistical test* 
Total     15.8 ( 6/38)  - 
Age(years)   
23 to 64       9.1 ( 1/11)  p=0.650 
65 to 90     18.5 ( 5/27)   
Mean daily dose(mg/day)   
100      0.0 ( 0/ 3) p=0.898 
> 100 to < 150     20.0 ( 1/ 5)  
150    19.0 ( 4/21)  
> 150 to < 300     0.0 ( 0/ 5)  
300    25.0 ( 1/ 4)  
Duration of treatment(day)   
4 to 14      33.3 ( 2/ 6)  p=0.410 
15 to 28      15.4 ( 2/13)   
29 to 84      10.5 ( 2/19)   
* Fisher exact test    
 
 
